Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4NY58)

Drug Name
SB-623 Drug Info
Synonyms (E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
Indication
Disease Entry ICD 11 Status REF
Cerebrovascular ischaemia 8B1Z Phase 2 [1]
Ischemic stroke 8B11.5Z Phase 2 [2]
Stroke 8B20 Phase 2 [3]
Traumatic brain injury NA07.Z Phase 2 [3]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
6918876
ChEBI ID
CHEMBL491491
TTD Drug ID
DM4NY58

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Histone deacetylase 1 (HDAC1) DTT HDAC1 6.206 8.094 7.236 7.56
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cerebrovascular ischaemia
ICD Disease Classification 8B1Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histone deacetylase 1 (HDAC1) DTT HDAC1 6.27E-01 0.11 0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02448641) Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.